Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus enoxaparin for prevention of thromboembolic events after gynecologic cancer surgery
IRCT20231026059867N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of apixaban and enoxaparin in thrombosis and pulmonary embolism (PE) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Thrombosis and Pulmonary embolism. Started Dec 2023; status: completed.
02
Drugs
apixabanenoxaparin
03
Conditions
thrombosispulmonary embolism (PE)
Beyond the preview
Go deeper on IRCT20231026059867N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231026059867N1.